Ishvan Pharmaceutical

Farm Aid Ltd, 49% of which belongs to the National Immunobiological Company and 51% - to the Pharmaceutical Ishvan UAE, will begin to doze out and package the vaccine for prevention of rotavirus infection in 2020. By this time, the Ministry of Healthcare plans to include the vaccine in the national calendar of preventive vaccination.

National Immunobiological Company reported the completion of the first phase of the clinical trials for the new vaccine created on the basis of technology transfer by Serum Institute of India. The full cycle, including the production of antigens, is expected to be launched in 2026.

11 September 2018

Investor profile

Ishvan Pharmaceutical


Private company

Contact: Sandjive Nanda, Managing Director

Ishvan Pharmaceuticals Ltd is a pharmaceutical company with a full production cycle, which manufactures innovative medicinal products, medical devices and diagnostics in developing countries around the world.